Ontology highlight
ABSTRACT:
SUBMITTER: Coleman HN
PROVIDER: S-EPMC4841729 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
Coleman Hannah N HN Greenfield William W WW Stratton Shawna L SL Vaughn Rita R Kieber Alexander A Moerman-Herzog Andrea M AM Spencer Horace J HJ Hitt Wilbur C WC Quick Charles Matthew CM Hutchins Laura F LF Mackintosh Samuel G SG Edmondson Ricky D RD Erickson Stephen W SW Nakagawa Mayumi M
Cancer immunology, immunotherapy : CII 20160315 5
In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase. As with the dose-escalation phase, no dose-limiting toxicities were observed. Overall, the histological regression rates were 50% at the 50 μg dose (7 of 14) and 100 μg dose (3 of 6), and 45 % overal ...[more]